AbCellera

About:

AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.

Website: https://www.abcellera.com

Twitter/X: abcellerabio

Top Investors: OrbiMed, Eli Lilly, Founders Fund, Bill & Melinda Gates Foundation, Viking Global Investors

Description:

AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner. With the integrated AbCellera platform, our experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set our partners up for enduring success.  We have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Total Funding Amount:

$887M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Vancouver, British Columbia, Canada

Founded Date:

2012-01-01

Founders:

Carl Hansen, Kevin Heyries, Véronique Lecault

Number of Employees:

501-1000

Last Funding Date:

2023-05-24

IPO Status:

Public

© 2025 bioDAO.ai